Rohde T, MacLean DA, Hartkopp A, Pedersen BK
Vyleesi is administered as a 1.75 mg subcutaneous injection taken as needed at least 45 minutes before anticipated sexual activity, with a maximum frequency of one dose per 24 hours and no more than eight doses per month
Regular use supports improved skin texture, enhanced radiance, and a naturally glowing complexion
This value was used to calculate (tau/Ka) values through normalization of the transduction coefficient (tau/Ka) for each ligand in each signalling pathway to the reference ligand (hGLP1 in black) and the reference signalling pathway (cAMP)
Despite their potential, peptides are not a magic cure-all
Ethics approval All animal experiments were approved by the Institutional Animal Care and Use Committee of Jeju National University (20230040)